LXEO Stock Summary and Trading Ideas (Lexeo Therapeutics | NASDAQ:LXEO)

Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.

Lexeo Therapeutics trades on the NASDAQ stock market under the symbol LXEO.

As of March 3, 2025, LXEO stock price declined to $2.34 with 1,080,306 million shares trading.

LXEO has a beta of 1.88, meaning it tends to be more sensitive to market movements. LXEO has a correlation of 0.07 to the broad based SPY ETF.

LXEO has a market cap of $77.36 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that LXEO belongs to (by Net Assets): VTI, VXF, IWM, VTWO, IWO.

LXEO has underperformed the market in the last year with a price return of -84.5% while the SPY ETF gained +16.7%. LXEO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -70.1% and -48.0%, respectively, while the SPY returned -2.2% and -4.3%, respectively.

LXEO support price is $2.64 and resistance is $3.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXEO shares will trade within this expected range on the day.